Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RENEW: Opicinumab in Acute Optic Neuritis
NCT01721161Phase 2Completed
- Sponsor
- Biogen
- Start
- Dec 2012
- Primary completion
- Oct 2014
- Modality
- Monoclonal Antibodies
- Countries
- 11
01
Overview
Phase 2, randomised, double-blind trial in optic neuritis (ON) comparing BIIB033 with Placebo (2 arms). Primary endpoint: Change in Full-field Visual Evoked Potential Latency at 24 weeks. Started Dec 2012; status: completed.
02
Drugs
opicinumab
03
Conditions
optic neuritis (ON)
Beyond the preview
Go deeper on NCT01721161.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01721161.